Navigation Links
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma
Date:3/3/2010

For diagnostic and monoclonal antibody production, Zap-Hybridoma improves target antibody purity and hybridoma productivity.

Fort Collins, CO (PRWEB) March 3, 2010 -- InVitria’s launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture. Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.

Zap-Hybridoma was developed by InVitria’s Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture. “Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum),” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”

“Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently,” said Scott Deeter, InVitria President and CEO. "We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”
                                                                                                                                                                                
Zap-Hybridoma / FBS
IgG Free                                                                                YES / NO
Consistent Performance                                                    YES / NO
Defined & Animal Component-Free                                YES / NO
Accelerates Adaptation to Serum-Free Media                YES / NO
Lowers Operating & Capital Costs                                   YES / NO
   
To order your sample of Zap-Hybridoma or to receive more information, please visit Zap-Hybridoma.

About InVitria – InVitria.com
InVitria specializes in cell culture media optimization for the biotechnology industry. InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s product solutions, e-mail info(at)InVitria(dot)com or call 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/ZapHybridoma/InVitria/prweb3678694.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. InVitria Sponsors 2010 Biomanufacturing Summit
2. Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance
3. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
4. InVitria Reveals Technology to Optimize Hybridoma Production Performance
5. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
6. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
7. InVitrias Cellastim Delivers Superior Results in Mammalian Cell Culture
8. InVitria Touts Product Advantages at Cambridges Cell Culture Conference
9. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
10. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
11. InVitria Expands Sales Team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma  
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):